



**For Immediate Release**  
December 3, 2013

**Contact:** Lisa DeMoss  
Director of Marketing  
615-695-4934

## **PATHGROUP EXPANDS FOOTPRINT WITH TWO NEW DEDICATED LABORATORIES**

**BRENTWOOD, Tenn.** – PathGroup, one of the largest private providers of pathology services in the United States, announced today that it has opened two new state-of-the-art facilities dedicated exclusively to molecular and cytology testing. The new laboratories are adjacent to PathGroup’s current laboratory at 658 Grassmere Park in Nashville, Tenn.

The two additional testing sites have the capability to perform molecular assays for oncology, including Next-Generation Sequencing (NGS), as well as infectious disease and women’s health diagnostics. The new space also includes a CLIA-validation laboratory for test development and implementation. PathGroup will continue to operate out of its existing 40,000 square foot laboratory. These new additions add approximately 20,000 square feet of nearby laboratory space, thereby increasing operational facilities by 50%. To date, PathGroup has more than 85,000 square feet of space with operational and corporate headquarters based in Middle Tennessee.

“In order to provide better service to our clients and the patients they serve, it was clear we needed to expand the PathGroup campus to support continued growth,” said Chuck Locke, Senior Vice President and Chief Operating Officer for PathGroup. “With the addition of the molecular and cytology laboratories, our expert staff will be better equipped to effectively accommodate increased volume and optimize workflow. Ultimately, this will drive improved patient outcomes through high-quality, high-service diagnostics and fast, accurate results.”

The dedicated cytology laboratory occupies 8,400 square feet of testing space on PathGroup’s campus. Cytopathology, used to aid in the diagnosis of cancer, infectious diseases and inflammatory conditions, is a key component of PathGroup’s broad offering. PathGroup employs a team of board-certified cytopathologists and experienced cytotechnologists. With a comprehensive menu and diagnostic expertise, PathGroup is a leading provider of women’s health services.

The 12,200 square foot molecular diagnostics laboratory neighbors both labs and offers the latest in genomic profiling, including Next-Generation Sequencing (NGS), in addition to the extensive menu of molecular assays offered today. The space also has the means to validate new tests and accelerate physician access. The addition of genomic profiling allows oncologists and pathologists to gain critical insights into disease which has become refractory to therapy as well as reveal potential treatments based upon specific genetic alterations.

“As a leading pathology services provider, we continue to advance the organization to meet the needs of the evolving healthcare landscape,” said Ben Davis, MD, PathGroup’s Chairman, President and CEO. “We felt it was imperative that we commit space and resources that will enable PathGroup to stay at the forefront of advances in laboratory medicine. We will continue to provide high quality care and adapt to the ever changing healthcare industry.”

### **About PathGroup**

Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services - a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. *One Lab; Total Service.* For more information, visit [www.pathgroup.com](http://www.pathgroup.com)

###